



Proventa International's 5th Annual

MEDICINAL CHEMISTRY STRATEGY MEETING WEST COAST USA 2023

📅 9th May 2023, Tuesday 📍 Hard Rock Hotel San Diego

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

BOOK NOW!

Featuring Industry Leaders and Decision Makers:



Abdulkader Rahmo
President and CSO
SMSbiotech
Regenerative Medicine



David Weinstein,
Vice President,
Head of Chemistry
Vividion
Therapeutics



Yuhua Ji
VP of Drug Discovery
Grace
Science LLC



Emily Stocking
Associate Director
Medicinal Chemistry
Neuropore
Therapies



Sampath Kumar Anandan
Vice President
of Discovery
Inipharma



Laurent Gomez
Vice President,
Head Of Chemistry
Entos



Devin Swanson
Principal Scientist,
External Innovation
The Janssen
Pharmaceutical
Companies of
Johnson & Johnson



Leo Kirkovsky
Director
Clinical Assay
Pfizer



20
ROUNDTABLE
DISCUSSIONS



5
TRACKS



2
KEYNOTE
PRESENTATIONS



1
LOCATION



**Hotel
Venue**



**Hard Rock
HOTEL**
SAN DIEGO

What Makes
Our Strategy
Meetings
So Unique?



Proud to Partner with:



Scan to register



Proventa International's Strategy Meetings are a completely unique experience.

MEDICINAL CHEMISTRY

STRATEGY MEETING WEST COAST USA 2023

9th May 2023, Tuesday @ Hard Rock Hotel San Diego

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.



Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.



Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format



ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.



PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.



INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.




STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Seniority of Attendees

- Director Level
- Department Head
- C-Level
- Other
- Academia
- Scientist
- President / VP
- Team Lead
- Manager



Medicinal Chemistry

- ✓ Medicinal Chemistry
- ✓ R&D
- ✓ Drug Discovery
- ✓ Computational Chemistry
- ✓ Cheminformatics
- ✓ CMC
- ✓ External Innovation
- ✓ Pre-Clinical
- ✓ Artificial Intelligence

Meet Investors

- ✓ Venture Capital
- ✓ Private Equity
- ✓ Large Pharma/Biotech
- ✓ Corporate Venture Capital
- ✓ Institutional
- ✓ High Net Worth
- ✓ Family Office/Private Wealth
- ✓ Government Organisation/Sovereign Wealth Fund
- ✓ Angel

BOOK NOW!

proventainternational.com

UK: +44 (0)20 3314 0100 | US: +1 (617) 614 0377

info@proventainternational.com



Facilitator Faculty

MEDICINAL CHEMISTRY

STRATEGY MEETING WEST COAST USA 2023

📅 9th May 2023, Tuesday 📍 Hard Rock Hotel San Diego



Jason Deng
Senior Director
WuXi Apptec



Matthew Segall
CEO
Optibrium



Abdulkader Rahmo
President and CSO
SMSbiotech
Regenerative Medicine



Andrea Small-Howard
President
GB Sciences



Laurent Gomez
Vice President,
Head Of Chemistry
Entos



Joshua Kunken
Associate Director,
R&D AI/ML
Takeda



David Weinstein
Vice President,
Head of Chemistry
Vividion
Therapeutics



Devin Swanson
Principal Scientist,
External Innovation
The Janssen
Pharmaceutical
Companies of
Johnson & Johnson



Don Hertzog
Head of Chemistry
Inception
Therapeutics



Emily Stocking
Associate Director
Medicinal Chemistry
Neuropore Therapies



Jian Zhao
Senior Director - Chemistry
Crinetics
Pharmaceuticals



Leo Kirkovsky
Director Clinical Assay
Pfizer



Sampath Kumar Anandan
Vice President of
Discovery
Inipharm



Venkat Bollu
Director
Ventyx Biosciences



Yuhua Ji
VP of Drug Discovery
Grace Science LLC

How Has Our
STRATEGY MEETINGS
Benefit The Life Science Industry

“

It was a great meeting. I enjoyed the round tables and seeing some old colleagues and meeting some new ones and continuing my string of attending every single one of your events from the first one!”

Mark Tebbe — Co-Founder & CSO, **Quench Bio**

“

The meeting was excellent. Discussions were great and trying to get everyone around the table to participate made for great idea sharing.”

Joseph Mancini —
Head of Pharmacology, **AdMare Bioinnovations**

BOOK NOW!

proventainternational.com

📞 UK: +44 (0)20 3314 0100 | US: +1 (617) 614 0377

✉ info@proventainternational.com



PROVENTA
INTERNATIONAL

THOUGHT LEADER



Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines with our partners by 2025. Sai Life Sciences provides services to our pharma innovator partners, which accelerate the discovery, development and manufacture of complex small molecule therapeutic agents. Our clients gain clear competitive advantages through shorter time to market and risk minimization using our integrated and high-quality scientific services. Established in 1999, Sai has over 2,000 employees located at six R&D and manufacturing sites in India, the UK and USA. As one of India's fastest growing CDMOs, the company is investing over US \$ 150 M in augmenting its R&D and manufacturing capabilities, including setting up a Biology Lab in Cambridge, Mass. (USA) and a Process R&D Lab in Manchester, UK. Sai provides high value integrated services in all areas of chemistry from hit discovery to GMP manufacturing, pharmacology, DMPK, toxicology and formulation development to better support the increasing needs of our customers. Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.

CO-HOST SPONSORS



WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

<http://www.wuxiapptec.com>



Optibrium develops cutting-edge software for small molecule design, optimisation and data analysis. Their lead product, StarDrop™, is a comprehensive suite of integrated software that enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research. Cerella™, Optibrium's proven AI, guides successful drug discovery, generating valuable insights from your data, whilst Inspyra™ combines your expert chemistry knowledge with the exploratory power of generative AI methods to create, evaluate and optimise novel compound ideas. Optibrium was founded in 2009 in Cambridge, UK, with a US subsidiary, Optibrium Inc., in Cambridge, MA. The company works with over 180 customers and collaborators, including leading global pharma, biotech, agrochemical companies and academic groups.



Chemaxon is a leading cheminformatics company, with headquarters in Budapest, Hungary and offices in the US and Switzerland. And what do we do? We provide chemical software development platforms mostly for the biotechnology and pharmaceutical industries - but any chemist might find us useful. Why do our users prefer us? Because we are known for our rapid and high quality technical support, we develop our tools together with our users (the reason we have good quality software); and because we support academic research and teaching like no one else in the industry! All right, so exactly what are we good for? Well, among many other things, you can draw & view chemical structures with Marvin Suite; manage and search your compounds with JChem tools; search your database in Excel or in our Instant JChem interface; perform a variety of calculations and predictions; cluster, screen, fragment or synthesize your compounds virtually and deal with Markush structures.



Piramal Pharma Solutions (PPS) is a Contract Research Development and Manufacturing Organization (CDMO) offering end-to-end discovery, development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. The Discovery Services site of PPS has been operational since 2003 in Ahmedabad, India and currently have ~300+ chemistry FTE's and ~25 Biologists supporting various small molecule discovery programs in Hit to Lead and Lead Optimization stages and work on both FTE and Fee Based Models. Our capabilities include:

- Custom Synthesis of individual compounds, building blocks, scaffolds, focused libraries (40-100 compounds), reference standards, intermediates, impurities & metabolites
- DMPK
- Route Scouting leveraging our global process chemistry expertise across US, Canada & India to support early drug development
- Analytical services including method development (non-GMP), separation of Chiral/ Achiral compounds (mg-gm scale)

PPS also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product from 14 sites in India, UK, Canada and USA. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide. PPS is a subsidiary of the India based Healthcare and Financial Conglomerate -Piramal Enterprises Ltd (Market Cap - \$5 Billion) and the Carlyle Group has recently acquired a 20% stake in PPS. For more information please visit: www.piramalpharmasolutions.com



Aragen Life Sciences is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. We offer end-to-end integrated or standalone solutions for small and large molecules. Established in 2001, we now operate through our network of sites located globally with a team of 3700+ scientists and 475+ PhDs. Our expertise and experience have enabled over 450+ customers in advancing their research programs from discovery through commercialization. Aragen's innovative mindset, infrastructure, flexible business models have enabled us to serve large pharma or biotech, agrochemical, animal health and performance chemical industries globally. All our facilities conform to stringent regulatory standards. Our infrastructure has a built-up area of 1.2 million square feet, housing chemistry and biology labs, AALAC-accredited animal houses, analytical labs, formulation development labs, kilo labs, pilot plants and manufacturing facilities. Aragen has been inspected by all leading regulatory agencies of the world, including USFDA, WHO, PMDA, EDQM and EMEA. Aragen has submitted its letter of intent to the Science Based Targets initiative (SBTi) and is part of a growing list of organizations that are committed to setting emission reduction targets in line with the Paris Agreement to limit global warming. It is also a signatory to the GRI South Asia Charter on Sustainability Imperatives, a framework that helps to realize the 17 Sustainable Development Goals (SDGs) defined by the United Nation. We are proud to be a Great Place to Work® (GPTW) certified company for the third consecutive year in 2022. This recognition confirms our High-Trust, High-Performance Culture™ and places us among 'companies with the best culture' to work with. For more details, visit www.aragen.com



Jubilant Biosys was founded in 2003 and serves the global pharma industry with over 2300 employees operating from 5 sites in India. Biosys is recognised for its scientific innovation and collaborative drug discovery programs with leading pharma and biotech companies due to its deeply ingrained science-led service culture. Jubilant Biosys has developed a deep level of expertise in discovery informatics, computational chemistry, medicinal chemistry, structural biology, biology, in-vivo, in-vitro models and translational sciences. In a proactive initiative to keep pace with the ever evolving R&D industry landscape, Biosys has consolidated advances in Chemistry by utilizing the latest AI/ML technologies and by incorporation of environment friendly processes. This enables Biosys to partner with leading companies on the most challenging, cost and time sensitive drug discovery programs. Given the strong revenue growth, Biosys is investing to further expand Chemistry, Integrated Drug Discovery and CDMO services. Our recently commissioned research centre near Delhi is a world-leading infrastructure for Chemistry & DMPK Services. With a strong commitment to new technologies, supply chain, quality and ESG considerations, Biosys is becoming the preferred CRDMO partner in India for Big Pharma companies.






















KEY OPINION LEADERS





Agenda at a Glance

MEDICINAL CHEMISTRY
STRATEGY MEETING WEST COAST USA 2023
9th May 2023, Tuesday 📍 Hard Rock Hotel San Diego

	TRACK 1	TRACK 2	TRACK 3	TRACK 4	TRACK 5
TIME	AI/ML	INNOVATIVE AND EMERGING MODALITIES	CHEMICAL BIOLOGY AND UNDRUGGABLES	HIT IDENTIFICATION / LEAD OPTIMIZATION	INTEGRATED DRUG DISCOVERY
PT					
08:00 - 08:30	BREAKFAST & REGISTRATION				
08:30 - 09:00	OPENING KEYNOTE PRESENTATION DRUG DESIGN AND DISCOVERY IN THE AGE OF ARTIFICIAL INTELLIGENCE  PRESENTER: Andrea Small-Howard, <i>President, GB Sciences</i>				
09:00 - 10:00	The 2023 AI Update  Andrea Small-Howard, <i>President, GB Sciences</i>	Big Drugs, Little Drugs - Exploring The Power of Large Molecule Improvements In Discovering Novel Drug Therapies  Jian Zhao, <i>Senior Director - Chemistry, Crinetics Pharmaceuticals</i>	Utilizing The New Warheads: Strategic Ways Of Developing Targeted Covalent Drugs  Don Hertzog, <i>Head of Chemistry, Inception Therapeutics</i>	Leveraging Predictive Model Techniques To Accelerate Hit-To-Lead Optimization  Laurent Gomez, <i>Vice President, Head Of Chemistry, Entos</i>	Discovering New Drug Discovery Endpoints: Challenges And Opportunities (TBC)  Emily Stocking, <i>Associate Director Medicinal Chemistry, Neuropore Therapies</i>
10:00 - 10:10	REFRESHMENT BREAK				
10:10 - 10:30	NETWORKING / 1-1 MEETINGS				
10:30 - 10:50	NETWORKING / 1-1 MEETINGS				
10:50 - 11:10	NETWORKING / 1-1 MEETINGS				
11:10 - 12:10 SOLUTION	AI in Drug Discovery Chemistry: From Promise to Practice  Matthew Segall, <i>CEO, Optibrium</i> OPTIBRIUM 		Converting Undruggable Targets to Druggable – where are we today? SAI LIFE SCIENCES 	Emerging Technologies in Hit Identification and Lead Optimization  Jason Deng, <i>Senior Director, WuXi AppTec</i> WUXI APPTec 	Overview of Fragment-Based Drug Discovery for Productivity and Improvement: Is There Panache Behind the Problems? SAI LIFE SCIENCES 
12:10 - 13:10	NETWORKING LUNCH				
13:10 - 14:10	Integrating AI/ML and Deep Learning For Early Phase Drug Development  Joshua Kunken, <i>Associate Director, R&D AI/ML, Takeda</i>	How Strategic R&D Partnerships And Alliances Can Fast Track R&D Projects In A Co-Development Program  Devin Swanson, <i>Principal Scientist, External Innovation, The Janssen Pharmaceutical Companies of Johnson & Johnson</i>	Developing PROTAC Drugs: Fabricating Strategies for DMPK and ADMET To Overcome Challenges And Limitations  David Weinstein, <i>Vice President, Head of Chemistry, Vividion Therapeutics</i>	Investigating Best Strategies To Accelerate The Progress of Compounds From Hit Identification Into Lead Optimization  Sampath Kumar Anandan, <i>Vice President of Discovery, Inpharm</i>	Challenges and advantages in integration of solid-state properties in lead optimization for effective drug development  Venkat Bollu, <i>Director, Ventyx Biosciences</i>
14:10 - 14:20	REFRESHMENT BREAK				
14:20 - 14:40	NETWORKING / 1-1 MEETINGS				
14:40 - 15:00	NETWORKING / 1-1 MEETINGS				
15:00 - 15:20	NETWORKING / 1-1 MEETINGS				
15:20 - 16:20		What is the current and a future role of Medicinal Chemistry in new combo therapeutic modalities such as ADC, nanoparticles and especially in “pure” biologics such as gene therapy, etc.?  Leo Kirkovsky, <i>Director Clinical Assay, Pfizer</i>	How New Biologics Can Overcome The Undruggable Challenge  Abdulkader Rahmo, <i>President and CSO, SMSbiotech Regenerative Medicine</i>	Overlooked Components Of Drug Discovery/ Optimization That Contributes To Clinical Drug Development Failure Rates: True Target Validation And Current Drug Optimization - Best Approach To Eradicate These Difficulties  Yuhua Ji, <i>VP of Drug Discovery, Grace Science LLC</i>	Revitalizing Drug Discovery with BRo5 Molecules: An Exploration of Large Molecule Enhancements In The Search for Innovative Drug Therapie  Devin Swanson, <i>Principal Scientist, External Innovation, The Janssen Pharmaceutical Companies of Johnson & Johnson</i>
16:20 - 17:20	DRINKS & CANAPES RECEPTION				

BOOK NOW!

proventainternational.com

📞 UK: +44 (0)20 3314 0100 | US: +1 (617) 614 0377

✉ info@proventainternational.com



MEDICINAL CHEMISTRY

STRATEGY MEETING WEST COAST USA 2023

📅 9th May 2023, Tuesday 📍 Hard Rock Hotel San Diego

Hotel & Venue



SAN DIEGO

Hard Rock Hotel San Diego

You're the main act in San Diego. At Hard Rock Hotel, we immerse you in our musical amenities, world-class service, and intoxicating location in

HOTEL DISCOUNTED RATE: **\$299 USD** only

BOOK NOW!
We only have limited rooms available!

[Hotel Details >](#)

[Map & Directions >](#)



OUR FACE-TO-FACE MEETING IN MAY 2023

Strategy Meeting San Diego, Boston & Princeton USA

**MAY
2023**

San Diego - US West Coast

08th - Drug Discovery Biology Strategy Meeting
09th - Medicinal Chemistry Strategy Meeting
10th - Oncology Strategy Meeting
11th - Clinical Operations Strategy Meeting

**MAY
2023**

Boston/Cambridge MA - US East Coast

17th - Regulatory Affairs Strategy Meeting
18th - Chemistry, Manufacturing and Controls Strategy Meeting

**MAY
2023**

Princeton New Jersey - US East Coast

23rd - Drug Discovery Biology Strategy Meeting
24th - Medicinal Chemistry Strategy Meeting
25th - Clinical Operations Strategy Meeting

Visit us on our website to know more about our meetings
www.proventainternational.com